Central European Institute of Technology Masaryk University Brno Czech Republic

Central European Institute of Technology Masaryk University Brno Czech Republic; Department of Internal Medicine Hematology and Oncology University Hospital Brno and Faculty of Medicine Masaryk University Brno Czech Republic

Department of Internal Medicine Hematology and Oncology University Hospital Brno and Faculty of Medicine Masaryk University Brno Czech Republic

Department of Medical Oncology Dana Farber Cancer Institute Boston MA USA

Zobrazit více v PubMed

Pavlasova G, Mraz M. The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy. Haematologica. 2020;105(6):1494-1506. PubMed PMC

Burger JA, Sivina M, Jain N, et al. . Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019;133(10):1011-1019. PubMed PMC

Pavlasova G, Borsky M, Seda V, et al. . Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood. 2016;128(12):1609-1613. PubMed PMC

Skarzynski M, Niemann CU, Lee YS, et al. . Interactions between ibrutinib and anti-CD20 Antibodies: competing effects on the outcome of combination therapy. Clin Cancer Res. 2016;22(1):86-95. PubMed PMC

Pyrzynska B, Dwojak M, Zerrouqi A, et al. . FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy. Oncoimmunology. 2018;7(5):e1423183. PubMed PMC

Furman RR, Sharman JP, Coutre SE, et al. . Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997-1007. PubMed PMC

Pavlasova G, Borsky M, Svobodova V, et al. . Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels. Leukemia. 2018;32(9):2028-2031. PubMed

Guo BC, Zhang L, Chiorazzi N, Rothstein TL. IL-4 rescues surface IgM expression in chronic lymphocytic leukemia. Blood. 2016; 128(4):553-562. PubMed PMC

Venugopal P, Sivaraman S, Huang XK, Nayini J, Gregory SA, Preisler HD. Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk Res. 2000; 24(5):411-415. PubMed

Guo BC, Rothstein TL. B cell receptor (BCR) cross-talk: IL-4 creates an alternate pathway for BCR-induced ERK activation that is phosphatidylinositol 3-kinase independent. J Immunol. 2005; 174(9): 5375-5381. PubMed

Bilancio A, Okkenhaug K, Camps M, et al. . Key role of the p110 delta isoforrn of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110 delta function in B cells. Blood. 2006;107(2):642-650. PubMed

Herman SEM, Gordon AL, Wagner AJ, et al. . Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116(12):2078-2088. PubMed PMC

Morsy DE, Sanyal R, Zaiss AK, Deo R, Muruve DA, Deans JP. Reduced T-Dependent Humoral Immunity in CD20-Deficient Mice. J Immunol. 2013;191(6):3112-3118. PubMed

Golay J, Lazzari M, Facchinetti V, et al. . CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 2001;98(12):3383-3389. PubMed

Campagne MV, Wiesmann C, Brown EJ. Macrophage complement receptors and pathogen clearance. Cell Microbiol. 2007;9(9):2095-2102. PubMed

Da Roit F, Engelberts PJ, Taylor RP, et al. . Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica. 2015; 100(1): 77-86. PubMed PMC

FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia

Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs

In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing